Jeffrey K Harrison

Jeffrey K Harrison, Ph.D.

PROFESSOR

Department: MD-PHARMACOLOGY / THERAPEUTICS
Business Phone: (352) 627-9208
Business Email: jharriso@ufl.edu

Research Profile

The Harrison Lab is interested in understanding the functional significance of chemokine networks in the central nervous system with a primary focus on determining roles for these molecules in malignant brain cancers such as glioblastoma. Dr. Harrison studies mechanisms involved in tumor-immune cell interactions as well as direct effects of chemokines on glioma initiating cells. Experimental approaches encompass in vitro and in vivo methods and include the use of chemokine receptor selective pharmacological agents.

Publications

2021
Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.
Pharmacology & therapeutics. 222 [DOI] 10.1016/j.pharmthera.2020.107790. [PMID] 33316289.
2020
Adult immuno-oncology: using past failures to inform the future.
Neuro-oncology. 22(9):1249-1261 [DOI] 10.1093/neuonc/noaa116. [PMID] 32391559.
2020
CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Proceedings of the National Academy of Sciences of the United States of America. 117(2):1129-1138 [DOI] 10.1073/pnas.1910856117. [PMID] 31879345.
2018
Involvement of Microglial Cells in Hypoxia-induced Pulmonary Hypertension.
American journal of respiratory cell and molecular biology. 59(2):271-273 [DOI] 10.1165/rcmb.2018-0042LE. [PMID] 30067089.
2017
Erratum to: CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes.
Journal of molecular medicine (Berlin, Germany). 95(5):565-566 [DOI] 10.1007/s00109-017-1530-8. [PMID] 28421250.
2016
Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells.
Hypertension (Dallas, Tex. : 1979). 67(3):574-84 [DOI] 10.1161/HYPERTENSIONAHA.115.06474. [PMID] 26781279.
2016
CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes.
Journal of molecular medicine (Berlin, Germany). 94(11):1255-1265 [DOI] 10.1007/s00109-016-1433-0. [PMID] 27344677.
2015
Microglia Activate Migration of Glioma Cells through a Pyk2 Intracellular Pathway.
PloS one. 10(6) [DOI] 10.1371/journal.pone.0131059. [PMID] 26098895.
2015
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Cancer letters. 360(1):60-7 [DOI] 10.1016/j.canlet.2015.02.005. [PMID] 25676691.
2014
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.
Frontiers in cellular neuroscience. 8 [DOI] 10.3389/fncel.2014.00144. [PMID] 24904289.
2014
Detection of primary cilia in human glioblastoma.
Journal of neuro-oncology. 117(1):15-24 [DOI] 10.1007/s11060-013-1340-y. [PMID] 24510433.
2014
Signaling mechanisms that suppress the cytostatic actions of rapamycin.
PloS one. 9(6) [DOI] 10.1371/journal.pone.0099927. [PMID] 24927123.
2013
Expression and functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patient-derived glioblastoma cells.
PloS one. 8(3) [DOI] 10.1371/journal.pone.0059750. [PMID] 23555768.
2012
A model of GAG/MIP-2/CXCR2 interfaces and its functional effects.
Biochemistry. 51(28):5642-54 [PMID] 22686371.
View on: PubMed
2012
CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5.
Journal of neuroimmunology. 246(1-2):10-7 [DOI] 10.1016/j.jneuroim.2012.02.009. [PMID] 22425022.
2012
CXCR3 antagonism of SDF-1(5-67) restores trabecular function and prevents retinal neurodegeneration in a rat model of ocular hypertension.
PloS one. 7(6) [DOI] 10.1371/journal.pone.0037873. [PMID] 22675496.
2012
Hypoxia-induced endothelial CX3CL1 triggers lung smooth muscle cell phenotypic switching and proliferative expansion.
American journal of physiology. Lung cellular and molecular physiology. 303(10):L912-22 [DOI] 10.1152/ajplung.00014.2012. [PMID] 23002075.
2011
Chemokine receptor CXCR3 promotes growth of glioma.
Carcinogenesis. 32(2):129-37 [DOI] 10.1093/carcin/bgq224. [PMID] 21051441.
2011
Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats.
Neurobiology of aging. 32(11):2030-44 [DOI] 10.1016/j.neurobiolaging.2009.11.022. [PMID] 20018408.
2010
Cx3Cr1 Microglial Receptor Modulates Hippocampal Synaptic Plasticity
Cell Transplantation. 19
2009
Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest.
Differentiation; research in biological diversity. 78(1):35-44 [DOI] 10.1016/j.diff.2009.04.001. [PMID] 19427096.
2009
Hematopoietic- and neurologic-expressed sequence 1 expression in the murine GL261 and high-grade human gliomas.
Pathology oncology research : POR. 15(3):437-44 [DOI] 10.1007/s12253-008-9147-4. [PMID] 19145478.
2008
CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes.
Journal of neuroimmunology. 198(1-2):98-105 [DOI] 10.1016/j.jneuroim.2008.04.016. [PMID] 18508133.
2008
Hn 1 Is a Novel Actin Complex-Binding Protein That Regulates B16.F10 Melanoma Cell Growth and Secretion of Melanin
Pigment Cell and Melanoma Research. 21:333-334
2008
Structure-Based Jaz Ligand-Ji and Its Analogues Show Strong Cytotoxic Effects On Glioma Cells in Vitro – a New Class of Glioma Therapy Drugs?
Journal of Neuropathology and Experimental Neurology. 67
2006
Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes.
Diabetes. 55(1):102-9 [PMID] 16380482.
View on: PubMed
2006
Proline 326 in the C terminus of murine CX3CR1 prevents G-protein and phosphatidylinositol 3-kinase-dependent stimulation of Akt and extracellular signal-regulated kinase in Chinese hamster ovary cells.
The Journal of pharmacology and experimental therapeutics. 316(1):356-63 [PMID] 16166268.
View on: PubMed
2005
Role of fractalkine (CX3CL1) in regulating neuron-microglia interactions: development of viral-based CX3CR1 antagonists.
Current Alzheimer research. 2(2):187-9 [PMID] 15974917.
View on: PubMed
2005
The facial motor nucleus transcriptional program in response to peripheral nerve injury identifies Hn1 as a regeneration-associated gene.
Journal of neuroscience research. 82(5):581-91 [PMID] 16267826.
View on: PubMed
2005
Transforming growth factor-beta1 increases CXCR4 expression, stromal-derived factor-1alpha-stimulated signalling and human immunodeficiency virus-1 entry in human monocyte-derived macrophages.
Immunology. 114(4):565-74 [PMID] 15804293.
View on: PubMed
2004
Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.
Journal of virology. 78(12):6595-609 [PMID] 15163751.
View on: PubMed
2004
Viral macrophage inflammatory protein-II and fractalkine (CX3CL1) chimeras identify molecular determinants of affinity, efficacy, and selectivity at CX3CR1.
Molecular pharmacology. 66(6):1431-9 [PMID] 15361546.
View on: PubMed
2004
Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone.
Archives of ophthalmology (Chicago, Ill. : 1960). 122(12):1801-7 [PMID] 15596583.
View on: PubMed
2003
Chemokine receptor binding and signal transduction in native cells of the central nervous system.
Methods (San Diego, Calif.). 29(4):326-34 [PMID] 12725799.
View on: PubMed
2003
Developmental expression of mouse muscleblind genes Mbnl1, Mbnl2 and Mbnl3.
Gene expression patterns : GEP. 3(4):459-62 [PMID] 12915312.
View on: PubMed
2003
In situ hybridization analysis of chemokines and chemokine receptors in the central nervous system.
Methods (San Diego, Calif.). 29(4):312-8 [PMID] 12725797.
View on: PubMed
2002
TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia.
Journal of neuroimmunology. 133(1-2):46-55 [PMID] 12446007.
View on: PubMed
2000
Histologic, neurologic, and immunologic effects of methylmercury in captive great egrets.
Journal of wildlife diseases. 36(3):423-35 [PMID] 10941726.
View on: PubMed
1999
Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart.
Journal of leukocyte biology. 66(6):937-44 [PMID] 10614775.
View on: PubMed
1996
Identification of two rat genes orthologous to the human interleukin-8 receptors.
Journal of Biological Chemistry. 271(51):32770-6 [DOI] 10.1074/jbc.271.51.32770. [PMID] 8955112.

Grants

Sep 2018 ACTIVE
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jul 2018 ACTIVE
Florida Center for Brain Tumor Research
Role: Project Manager
Funding: FL DEPT OF HLTH
Sep 2017 – Aug 2018
Optimizing systemic stem/progenitor cell therapy for AMD
Role: Principal Investigator
Funding: UNIV OF ALABAMA BIRMINGHAM via NATL INST OF HLTH NEI
Sep 2016 – Dec 2016
Bone Marrow Neuropathy Drive Diabetic Retinopathy
Role: Principal Investigator
Funding: INDIANA UNIV
Jul 2016 – Dec 2016
TO #1 – Evaluation of CXCR4 Antagonists in Pre-clinical Models of Glioblastoma
Role: Principal Investigator
Funding: X4 PHARMACEUTICALS
Jul 2016 – Jun 2018
Florida Center for Brain Tumor Research (FCBTR) Grant for 2016
Role: Co-Investigator
Funding: ACCELERATE BRAIN CANCER CURE
Sep 2015 – Aug 2016
Bone marrow neuropathy drives diabetic retinopathy
Role: Principal Investigator
Funding: INDIANA UNIV via NATL INST OF HLTH NEI
Feb 2015 ACTIVE
UF Health Cancer Center Pilot Project Grants funded through the Florida Consortium of National Cancer Institute Centers Program
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Dec 2014 – Mar 2017
irradiAnti-CXCR4 antibody combined with Avastin alone or Avastin and irradiation for GBM
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Jul 2014 – Jun 2016
Combining CXCR4, VEGFR, AND TGFBR inhibitors to synergistically inhibit GBM progression
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Jul 2013 – Aug 2017
Role of CX3CR1 and CCR2 in controlling microglia and mononuclear cells in AMD
Role: Principal Investigator
Funding: INDIANA UNIV via NATL INST OF HLTH
Jul 2013 – Jun 2016
Indiana non-federal expenditures for Bone Marrow Neuropathy Drives Diabetic Retinopathy
Role: Principal Investigator
Funding: INDIANA UNIV

Education

PhD
1988 · University of Michigan
BS
1983 · University of Michigan

Teaching Profile

Courses Taught
2019-2021
GMS6520 Medical Pharmacology and Therapeutics I: The Nervous System
2019-2021
GMS6530 Medical Pharmacology and Therapeutics II: Cardiovascular, Renal and Respiratory Systems
2014,2016-2018,2018-2021
GMS6001 Fundamentals of Biomedical Sciences I
2018-2021
GMS6560 Molecules to Man: Past, Present and Future Therapeutic Strategies for Disease
2020-2021
PAS5026 Pharmacotherapeu 2
2019-2021
GMS6551 Fundamentals of Medical Pharmacology and Therapeutics
2016-2021
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2007-2016,2019-2021
GMS6590 Seminar in Pharmacology
2011,2013-2016,2016-2021
GMS5905 Special Topics in Biomedical Sciences
2011-2021
DEN6262 Prin of Pharmacology
2015-2016,2018-2021,2020-2021
GMS6009 Principles of Drug Action and Therapeutics
2018
GMS7980 Research for Doctoral Dissertation
2015,2018
BMS6638C Kidney & Urinary Tract
2015-2017
GMS6895 CTS Journal Club
2006-2008,2010-2014,2012-2017,2016-2017
GMS6051 Signal Transduction
2014,2016
MDU4002 Introduction to Medical Science Seminar 2
2013-2014
BMS6031 Foundations of Med
2014
GMS6140 Principles of Immunology
2010
IDH4917 Undergrad Research

Contact Details

Phones:
Business:
(352) 627-9208
Emails:
Business:
jharriso@ufl.edu